Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
J Hum Hypertens. 2023 Jul;37(7):511-518. doi: 10.1038/s41371-022-00716-7. Epub 2022 Jul 5.
In Covid-19 pandemic, specific comorbidities are associated with the increased risk of worse outcomes and increased severity of lung injury and mortality. the aim of this study was to investigate the effects of antihypertensive medications on the severity and outcomes of hypertensive patients with COVID-19. This retrospective observational study conducted on patients with COVID-19 who referred to Afzalipour Hospital, Kerman, Iran during the six months from 19 February 2020 to 20 July 2020. The data were collected through medical chart reviews. We assessed 265 patients with Covid-19 and they stratified based on hypertension and type of antihypertension medications. The data were described and Student's t-test, Mann-Whitney U and Fisher exact test were run to compare the patients 'demographical and clinical information. The qualitative variables were compared using the by SPSS software version 23. The results of the present study showed that hypertension was a prevalent comorbidity among patients with COVID-19 and hypertensive patients compared to other patients without any comorbidity who were older (P-value: 0.03). The oxygen saturation was higher for the patients in the control group than hypertensive patients (P-value: 0.01). The severity of COVID-19 and its outcome were not different between the patients who took or did not take antihypertensive medications and also the type of antihypertensive medications. Hypertensive patients did not show any significant difference in survival, hospital stay, ICU admission, disease severity, and invasive medical ventilation in other normotensive patients with COVID-19.
在 COVID-19 大流行期间，特定的合并症与较差的结局风险增加以及肺部损伤和死亡率增加有关。本研究旨在探讨降压药物对 COVID-19 高血压患者严重程度和结局的影响。这是一项回顾性观察性研究，对 2020 年 2 月 19 日至 2020 年 7 月 20 日期间在伊朗克尔曼 Afzalipour 医院就诊的 COVID-19 患者进行了研究。通过病历回顾收集数据。我们评估了 265 例 COVID-19 患者，并根据高血压和降压药物类型对他们进行了分层。描述了数据，并使用学生 t 检验、Mann-Whitney U 检验和 Fisher 确切检验来比较患者的人口统计学和临床信息。使用 SPSS 软件版本 23 比较定性变量。本研究结果表明，高血压是 COVID-19 患者的常见合并症，与无任何合并症的其他患者相比，高血压患者年龄更大（P 值：0.03）。与高血压患者相比，对照组患者的血氧饱和度更高（P 值：0.01）。服用或未服用降压药物的患者以及降压药物类型对 COVID-19 严重程度及其结局无影响。与其他 COVID-19 正常血压患者相比，高血压患者在生存率、住院时间、入住 ICU、疾病严重程度和有创性医疗通气方面没有显著差异。
